TRML Tourmaline Bio, Inc.

Nasdaq www.tourmalinebio.com


$ 47.97 $ 0.02 (0.04 %)    

Friday, 24-Oct-2025 16:00:44 EDT
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 47.98
$ 47.97
$ 47.96 x 10,000
$ 48.00 x 25
$ 47.97 - $ 47.98
$ 11.56 - $ 48.27
628,786
na
1.23B
$ 1.64
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-02-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-19-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-31-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-17-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 06-14-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

BMO Capital analyst Kostas Biliouris downgrades Tourmaline Bio (NASDAQ:TRML) from Outperform to Market Perform and raises th...

Core News & Articles

Piper Sandler analyst Yasmeen Rahimi downgrades Tourmaline Bio (NASDAQ:TRML) from Overweight to Neutral and lowers the price...

Core News & Articles

Truist Securities analyst Robyn Karnauskas downgrades Tourmaline Bio (NASDAQ:TRML) from Buy to Hold and lowers the price tar...

Core News & Articles

Guggenheim analyst Yatin Suneja downgrades Tourmaline Bio (NASDAQ:TRML) from Buy to Neutral and lowers the price target from...

Core News & Articles

HC Wainwright & Co. analyst Yi Chen downgrades Tourmaline Bio (NASDAQ:TRML) from Buy to Neutral and lowers the price tar...

Core News & Articles

Chardan Capital analyst Daniil Gataulin downgrades Tourmaline Bio (NASDAQ:TRML) from Buy to Neutral and lowers the price tar...

Core News & Articles

LifeSci Capital analyst Rami Katkhuda downgrades Tourmaline Bio (NASDAQ:TRML) from Outperform to Market Perform and announce...

Core News & Articles

Jefferies analyst Roger Song downgrades Tourmaline Bio (NASDAQ:TRML) from Buy to Hold and lowers the price target from $64 t...

Core News & Articles

Wedbush analyst Laura Chico downgrades Tourmaline Bio (NASDAQ:TRML) from Outperform to Neutral and maintains the price targe...

 novartis-to-expand-heart-drug-portfolio-with-14-billion-tourmaline-bio-acquisition

Novartis agreed to acquire Tourmaline Bio for $1.4 billion as pacibekitug shows strong trial results for inflammation and cardi...

Core News & Articles

Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option fo...

Core News & Articles

Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protein with pacibekitug across cli...

Core News & Articles

Chardan Capital analyst Daniil Gataulin maintains Tourmaline Bio (NASDAQ:TRML) with a Buy and maintains $70 price target.

Core News & Articles

Guggenheim analyst Yatin Suneja reiterates Tourmaline Bio (NASDAQ:TRML) with a Buy and maintains $55 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION